WO 2004/026248

## WHAT IS CLAIMED IS:

1. A compound represented by Formula I

5

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

n and m are each independently 0, 1 or 2;

10

J is selected from  $NR^1$  or  $C(R^1)(R^2)$ ;

K is selected from  $NR^3$  or  $C(R^3)(R^4)$ ;

15

L is selected from  $NR^5$  or  $C(R^5)(R^6)$ ;

X is a bond, -C(O), -N(R<sup>14</sup>)-, -N(R<sup>14</sup>)-C(O)-, -C(O)-N(R<sup>14</sup>)-, -N(R<sup>14</sup>)-S(O)<sub>k</sub>-, -N(R<sup>14</sup>)-C(O)-NH- or -S(O)<sub>k</sub>-N(R<sup>14</sup>);

20

k is 0, 1 or 2;

 $R^{1}\ \text{and}\ R^{10}$  are each independently selected from the group consisting

of:

(1) C<sub>1-6</sub>alkyl,

25

- (2) C<sub>2-6</sub>alkenyl,
- (3)  $C_{2-6}$ akynyl,
- (4) C<sub>3-6</sub>cycloalkyl,
- (5) C<sub>1-6</sub>alkoxy,
- (6)  $C_{1-6}$ alkyl- $S(O)_{k-}$ , wherein k is 0, 1 or 2,

	(7) (8)	aryl, aryl C <sub>1-6</sub> alkyl,
	(9) (10)	HET, -C <sub>1-6</sub> alkyl-HET,
5	(11)	aryloxy,
	(12)	aroyloxy,
	(13)	aryl C2-6alkenyl,
	(14)	aryl C2-6alkynyl,
	(15)	hydrogen,
10	(16)	hydroxyl and
	(17)	cyano

15

20

wherein items (1) to (6) above and the alkyl portions of items (8) and (10) above and the alkenyl portion of item (13) above and the alkynyl portion of item (14) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, oxo, OR<sup>13</sup>, N(R<sup>14</sup>)<sub>2</sub>, C<sub>3-6</sub>cycloalkyl and C<sub>1-6</sub>alkyl-S(O)<sub>k</sub>-, wherein k is 0, 1 or 2, and

wherein items (7), (9), (11) and (12) above and aryl portion of items (8), (13) and (14) above and the HET portion of item (10) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of:

	(a)	halo,
·	(b)	OR13,
25	(c)	$N(R^{14})_2$ ,
	(d)	C <sub>1-6</sub> alkyl,
	(e)	C <sub>2-6</sub> alkenyl,
	<b>(f)</b>	C <sub>2-6</sub> akynyl,
	(g)	$C_{1-6}$ alkyl- $S(O)_{k-}$ , wherein k is 0, 1 or 2,
30	(h)	aryl,
	(i)	aryl-S(O) $k$ -, wherein k is 0, 1 or 2,
	(j)	HET,
	(k)	aryl C <sub>1-6</sub> alkyl,
	(1)	aroyl,
35	(m)	aryloxy,

- (n) aryl C<sub>1-6</sub>alkoxy,
- (o) CN and
- (p) C<sub>3-6</sub>cycloalkyl,

wherein items (d) to (g) and (p) above and the alkyl portions of item (k) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR<sup>13</sup> and N(R<sup>14</sup>)<sub>2</sub>, and

wherein items (h), (i), (j), (l) and (m) above and the aryl portions of items (k) and (n) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR13 and C1-4alkyl,

R2, R3, R4, R5 and R6 are each independently selected from the group

15 consisting of:

5

30

- (1) hydrogen,
- (2) halo,
- (3) C<sub>1-6</sub>alkyl,
- (4) C<sub>2-6</sub>alkenyl,
- 20 (5) C<sub>2-6</sub>akynyl,
  - (6) C<sub>3-6</sub>cycloalkyl,
  - (7)  $C_{1-6}$ alkoxy,
  - (8)  $C_{1-6}$ alkyl- $S(O)_{k-}$ , wherein k is 0, 1 or 2,
  - (9) aryl,
- 25 (10) aryl C<sub>1-6</sub>alkyl,
  - (11) HET and
  - (12)  $-C_{1-6}$ alkyl-HET,

wherein items (3) to (8) above and the alkyl portions of items (10) and (12) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo,  $OR^{13}$ ,  $N(R^{14})_2$  and  $C_{1-6}$ alkyl- $S(O)_k$ -, wherein k is 0, 1 or 2; and

wherein items (9) and (11) and the aryl portion of items (10) and the HET portion of item (12) are optionally substituted from one up to the maximum number of

substituable positions with a substituent independently selected from the group consisting of:

- (a) halo,
- (b)  $OR^{13}$ .
- (c)  $N(R^{14})_2$ ,
- (d) C<sub>1-6</sub>alkyl,
- (e) C<sub>2-6</sub>alkenyl,
- (f) C2:6akynyl and
- (g)  $C_{1-6}$ alkyl- $S(O)_{k-}$ , wherein k is 0, 1 or 2,

wherein items (d) to (g) above are optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR<sup>13</sup> and N(R<sup>14</sup>)<sub>2</sub>,

or R1 and R3 or R3 and R5 may be joined together to form a double bond;

15

20

25

30

5

R7 is selected from the group consisting of:

- (1) hydrogen,
- (2) OR 13,
- (3) C<sub>1-4</sub>alkyl,
- (4) aryl and
- (5) aryl C<sub>1-4</sub>alkyl,

wherein item (3) above and the alkyl portion of item (5) above are optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo,  $OR^{13}$  and  $N(R^{14})_2$ , and

wherein item (4) above and the aryl portion of item (5) above are optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of:

- (a) halo,
- (b)  $OR^{13}$ .
- (c)  $N(R^{14})_2$ ,
- (d) C<sub>1-6</sub>alkyl,
- 35 (e) C<sub>2-6</sub>alkenyl and

(f) C<sub>2-6</sub>akynyl,

wherein items (d) to (f) above are optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR<sup>13</sup> and N(R<sup>14</sup>)<sub>2</sub>;

each Y1, Y2 and Y3 are independently selected from the group consisting of:

- (1) hydrogen,
- (2)  $-O-R^9$ ,
- (3)  $-S(O)_k-R^9$ , wherein k is 0, 1 or 2,
- 10 (4) -C-W-R9, wherein W is O or S(O)k,
  - (5)  $-N(R^{15})2$ ,
  - (6)  $-S(O)_{k}-N(R^{15})_{2}$ ,
  - (7)  $-N(R^{15})-S(O)k-N(R^{15})_2$ ,
  - (8) NO<sub>2</sub>,
- 15 (9)  $-C(O)-R^{15}$ ,

5

30

- (10) -C(O)O-R15,
- (11) -CN,
- (12) halo,
- (13)  $-O-S(O)_k-R^{15}$  and
- 20 (14) C<sub>1-4</sub>alkyl, optionally substituted with from 1 to 6 halo groups,

with the proviso that when Y<sub>2</sub> is hydrogen, Y<sub>3</sub> is  $-C(O)-R^{15}$ , R<sup>15</sup> is C<sub>1-6</sub>alkyl and X is -C(O) then R<sup>10</sup> is not C<sub>1-6</sub>alkyl, and

25 with the proviso that when Y<sub>2</sub> is  $-C(O)-R^{15}$ , Y<sub>3</sub> is hydrogen, R<sup>15</sup> is C<sub>1-6</sub>alkyl and X is -C(O) then R<sup>10</sup> is not C<sub>1-6</sub>alkyl, and

with the proviso that when Y<sub>2</sub> and Y<sub>3</sub> are both hydrogen, X is a bond and R<sup>10</sup> is HET, then said HET is defined as a 5-membered aromatic or non-aromatic monocyclic ring containing 1-3 heteroatoms selected from O, S and N,

R<sup>8</sup> is selected from the group consisting of: hydrogen, C<sub>1</sub>-6alkyl, C<sub>1</sub>-6alkoxy, -C<sub>1</sub>-6alkyl-C(O)OH and -C<sub>1</sub>-6alkyl-C(O)O-C<sub>1</sub>-6alkyl, wherein the C<sub>1</sub>-6alkyl portion is optionally mono, di or tri substituted with halo; or where R<sup>8</sup> and

-XR10 together with the carbon atom to which they are attached form the spiro

R9 is selected from the group consisting of: hydrogen, C<sub>1-12</sub>alkyl and aryl, wherein C<sub>1-12</sub>alkyl and aryl are optionally substituted from one up to the maximum number of substituents with halo;

each R11, R12 and R16 is independently selected from the group consisting of:

- (1) hydrogen,
- (2) halo,
  - (3) C<sub>1-6</sub>alkyl,
  - (4) C<sub>2-6</sub>alkenyl,
  - (5) C<sub>1-6</sub>alkoxy and
  - (6) hydroxy,

15

10

wherein items (3) to (5) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo,  $OR^{12}$ ,  $N(R^{13})_2$  and  $C_{1-6}$ alkyl- $S(O)_k$ -, wherein k is 0, 1 or 2,

20

25

30

or R16 may additionally be hydrogen;

each R<sup>13</sup> and R<sup>14</sup> is independently selected from the group consisting of hydrogen and C<sub>1-4</sub>alkyl, optionally substituted from one up to the maximum number of substitutable positions with halo; and

each R<sup>15</sup> is independently selected from the group consisting of: hydrogen, C<sub>1-6</sub>alkyl, aryl and C<sub>1-12</sub>alkoxycarbonyl, wherein said C<sub>1-6</sub>alkyl and C<sub>1-12</sub>alkoxycarbonyl are optionally substituted from one up to the maximum number of substituable positions with halo and said aryl is optionally substituted from one up to

the maximum number of substituable positions with halo and C<sub>1</sub>-4alkyl, optionally substituted with 1-3 halo groups.

5

2. A compound according to Claim 1 wherein:

J is NR1;

10 K is NR3;

L is  $C(R^5)(R^6)$ ; and

 ${\it R}^{3}$  and  ${\it R}^{5}$  are joined together to form a double bond.

15

3. A compound according to Claim 1 of Formula Ia:

20

Ia

4. A compound according to Claim 1 wherein R<sup>1</sup> is phenyl or pyridyl said phenyl or pyridyl or optionally mono or di-substituted with a substituent independently selected from the group consisting of:

25

- (a) halo,
- (b) OCH<sub>3</sub>,
- (d) CH<sub>3</sub>,
- (e) CN.

5. A compound according to Claim 4 wherein R<sup>1</sup> is phenyl, optionally mono or di-substituted with halo.

6. A compound according to Claim 3 wherein Y<sub>1</sub> is hydrogen.

5

- 7. A compound according to Claim 3 wherein R<sup>16</sup> is hydrogen.
- 8. A compound according to Claim 6 wherein R<sup>12</sup> is hydrogen.
- 9. A compound according to Claim 3 wherein R<sup>7</sup> is methyl.
  - 10. A compound according to Claim 1 wherein X is a bond, -C(O), -N(R<sup>14</sup>)-, -N(R<sup>14</sup>)-C(O)-, -C(O)-N(R<sup>14</sup>)-, -N(R<sup>14</sup>)-C(O)-NH-; and
- 15 R<sup>14</sup> is hydrogen or methyl.
  - 11. A compound according to Claim 1 wherein X is a bond, -C(O),  $-N(R^{14})$ -,  $-N(R^{14})$ -C(O)-, -C(O)- $N(R^{14})$ -,  $-N(R^{14})$ - $-R^{14}$ -,  $-N(R^{14})$ - $-R^{14}$ -,  $-R^{14}$
- 20 R1 is phenyl, optionally mono or di-substituted with halo;

R7 is methyl.

R11 is hydrogen;

R12 is hydrogen;

R14 is hydrogen or methyl;

25 R16 is hydrogen; and

30

R10 are each independently selected from the group consisting of:

- (1) C<sub>1-4</sub>alkyl,
- (2) C<sub>2-4</sub>alkenyl,
- (3) C2-4akynyl,
- (4) C<sub>3-6</sub>cycloalkyl,
- (5) C<sub>1-4</sub>alkoxy,
- (6) aryl,
- (7) aryl C<sub>1-4</sub>alkyl,
- (8) HET,

 $\sigma = a$ 

- (9) -C<sub>1</sub>-4alkyl-HET,
- (10) aryloxy,
- (11) aroyloxy,
- (12) aryl C2\_4alkenyl,
- 5 (13) aryl C<sub>2-6</sub>alkynyl,

10

15

20

25

wherein items (1) to (5) above and the alkyl portions of items (7) and (9) above and the alkenyl portion of item (12) above and the alkynyl portion of item (13) above are optionally substituted with from one to three substituents independently selected from the group consisting of: halo,  $OR^{13}$ ,  $N(R^{14})_2$ ,  $C_{3-6}$ cycloalkyl and  $C_{1-6}$ alkyl- $S(O)_{k-}$ , wherein k is 0, 1 or 2, and

wherein items (6), (8), (10) and (11) above and aryl portion of items (7), (12) and (13) above and the HET portion of item (9) above are optionally substituted with from one to three substituents independently selected from the group consisting of:

- (a) halo,
- (b)  $OR^{13}$ ,
- (c)  $N(R^{14})_2$ ,
- (d) C<sub>1-4</sub>alkyl,
- (e) C<sub>2-4</sub>alkenyl,
- (f) C<sub>2-4</sub>akynyl,
- (g) aryl,
- (h) HET,
- (i) aryl C<sub>1</sub>-6alkyl,
- (j) aroyl,
  - (k) aryloxy,
  - (l) aryl C<sub>1-6</sub>alkoxy and
  - (m) CN,

wherein items (d) to (f) above and the alkyl portions of item (i) above are optionally substituted from with one to three substituents independently selected from the group consisting of: halo, OR13 and N(R14)2, and

wherein items (g), (h), (j) and (k) above and the aryl portions of items (i) and (l) above are optionally substituted with from one to three substituents independently selected from the group consisting of: halo, OR<sup>13</sup> and C<sub>1-4</sub>alkyl,

## 12. A compound according to Claim 1 of Formula Ib

Ib

10 wherein:

5

m is 0 or 1,

n is 0 or 1,

R1 is phenyl, optionally mono or di-substituted with halo;

R10 are each independently selected from the group consisting of:

- 15 (1)  $C_{1-6alkyl}$ ,
  - (2) C<sub>2-6</sub>alkenyl,
  - (3) C2-6akynyl,
  - (4) C<sub>3-6</sub>cycloalkyl,
  - (5) C<sub>1-6</sub>alkoxy,
- 20 (6)  $C_{1-6}$ alkyl- $S(O)_{k-}$ , wherein k is 0, 1 or 2,
  - (7) aryl,
  - (8) aryl C<sub>1</sub>-6alkyl,
  - (9) HET,
  - (10) -C<sub>1-6</sub>alkyl-HET,
- 25 (11) aryloxy,
  - (12) aroyloxy,
  - (13) aryl C2-6alkenyl,
  - (14) aryl C2-6alkynyl,
  - (15) hydrogen, and

## (16) hydroxy

5

15

20

25

30

35

wherein items (1) to (6) above and the alkyl portions of items (8) and (10) above and the alkenyl portion of item (13) above and the alkynyl portion of item (14) above are optionally substituted with from one to three substituents independently selected from the group consisting of: halo, OR13, N(R14)2, C3-6cycloalkyl and C1-6alkyl-S(O)k-, wherein k is 0, 1 or 2, and

wherein items (7), (9), (11) and (12) above and aryl portion of items (8), (13) and (14) above and the HET portion of item (10) above are optionally substituted with from one to three substituents independently selected from the group consisting of:

alo

- (b)  $OR^{13}$ ,
- (c)  $N(R^{14})_2$ ,
- (d) C<sub>1-6</sub>alkyl,
- (e) C2-6alkenyl,
- (f) C2-6akynyl,
- (g)  $C_{1-6}$ alkyl- $S(O)_{k-}$ , wherein k is 0, 1 or 2,
- (h) aryl,
- (i)  $aryl-S(O)_{k-}$ , wherein k is 0, 1 or 2,
- (j) HET,
- (k) aryl C<sub>1-6</sub>alkyl,
- (l) aroyl,
- (m) aryloxy,
- (n) aryl C<sub>1</sub>-6alkoxy and
- (o) CN,

wherein items (d) to (g) above and the alkyl portions of item (k) above are optionally substituted from one to three substituents independently selected from the group consisting of: halo,  $OR^{13}$  and  $N(R^{14})_2$ , and

wherein items (h), (i), (j), (l) and (m) above and the aryl portions of items (k) and (n) above are optionally substituted from one to three substituents independently selected from the group consisting of: halo, OR13 and C1-4alkyl,

each R13 and R14 is independently selected from the group consisting of hydrogen and C1-4alkyl, optionally substituted from one to three halo groups;

WO 2004/026248

5

20

R16 and each R11 are independently selected from the group consisting of:

- (1) hydrogen,
- (2) halo,
- (3) methyl,
- (4) methoxy, and
  - (5) hydroxy;

Y<sub>1</sub> and Y<sub>2</sub> are each selected from the group consisting of:

- (1) hydrogen,
- (2) hydroxy,
- 10 (3) halo,
  - (4) methyl,
  - (5)  $-NO_2$ ,
  - (6) -CN,
  - (6) mono, di or tri halo substituted methyl,

15 X is a bond, -C(O),  $-N(R^{14})$ -,  $-N(R^{14})$ -C(O)-, -C(O)- $N(R^{14})$ -,  $-N(R^{14})$ - $S(O)_k$ -,  $-N(R^{14})$ -C(O)-NH- or  $-S(O)_k$ - $N(R^{14})$ ;

- 13. A compound according to Claim 12 wherein Y<sub>1</sub>, R<sup>11</sup> and R<sup>16</sup> are each hydrogen.
  - 14. A compound according to Claim 12 of Formula Ic:

Ic

25 wherein

n is 0 or 1,

R1 is phenyl, optionally mono or di-substituted with halo;

R10 is selected from the group consisting of:

- (1) C<sub>1-6</sub>alkyl,
- 30 (2) C<sub>2-6</sub>alkenyl,

	(3)	C2-6akynyl,	
	(4)	C3_6cycloalkyl,	
	(5)	C <sub>1-6</sub> alkoxy,	
	(6)	$C_{1-6}$ alkyl- $S(O)_{k-}$ , wherein k is 0, 1 or 2,	
5	(7)	aryl,	
	(8)	aryl C <sub>1-6</sub> alkyl,	
	(9)	HET,	
	(10)	-C <sub>1-6</sub> alkyl-HET,	
	(11)	aryloxy,	
10	(12)	aroyloxy,	
	(13)	aryl C2-6alkenyl,	
	(14)	aryl C <sub>2-6</sub> alkynyl,	
	(15)	hydrogen, and	
	(16)	hydroxy	
15			
	wherein items (1) to	(6) above and the alkyl portions of items (8) and (10) above and	
	the alkenyl portion of item (13) above and the alkynyl portion of item (14) above are		
	optionally substitute	d with from one to three substituents independently selected from	
	the group consisting	of: halo, $OR^{13}$ , $N(R^{14})_2$ , $C_{3-6}$ cycloalkyl and $C_{1-6}$ alkyl- $S(O)_{k^-}$ ,	
20	wherein k is 0, 1 or 2	2, and	
	wherein items (7), (9	9), (11) and (12) above and aryl portion of items (8), (13) and (14)	

25 halo, (a) OR13, (b)  $N(R^{14})_2$ , (c) C<sub>1</sub>-6alkyl, (d) (e) C2-6alkenyl, 30 C<sub>2</sub>-6akynyl, (f) C<sub>1-6</sub>alkyl-S(O)<sub>k</sub>-, wherein k is 0, 1 or 2, (g) (h) (i)  $aryl-S(O)_{k-}$ , wherein k is 0, 1 or 2,

(j)

above and the HET portion of item (10) above are optionally substituted with from

one to three substituents independently selected from the group consisting of:

- (k) aryl C<sub>1-6</sub>alkyl,
- (l) aroyl,
- (m) aryloxy,
- (n) aryl C<sub>1-6</sub>alkoxy and
- (o) CN,

5

20

25

wherein items (d) to (g) above and the alkyl portions of item (k) above are optionally substituted with from one to three substituents independently selected from the group consisting of: halo,  $OR^{13}$  and  $N(R^{14})_2$ , and

wherein items (h), (i), (j), (l) and (m) above and the aryl portions of items (k) and (n) above are optionally substituted with from one to three substituents independently selected from the group consisting of: halo, OR13 and C1-4alkyl,

each R<sup>13</sup> and R<sup>14</sup> is independently selected from the group consisting of hydrogen and C<sub>1-4</sub>alkyl, optionally substituted with from one to three halos;

- 15 R16 and each R11 are independently selected from the group consisting of:
  - (1) hydrogen,
  - (2) halo,
  - (3) methyl,
  - (4) methoxy, and
  - (5) hydroxy;

Y<sub>1</sub> and Y<sub>2</sub> are each selected from the group consisting of:

- (1) hydrogen,
- (2) hydroxy,
- (3) halo,
- (4) methyl,
- (5)  $-NO_2$ ,
- (6) -CN,
- (6) mono, di or tri halo substituted methyl,

X is a bond, -C(O),  $-N(R^{14})$ -,  $-N(R^{14})$ -C(O)-, -C(O)- $N(R^{14})$ -,

30  $-N(R^{14})-S(O)_{k-}$ ,  $-N(R^{14})-C(O)-NH-$  or  $-S(O)_{k-}N(R^{14})$ ;

15. The compound according to Claim 13 wherein X is a bond, -C(O),  $-N(R^{14})$ -,  $-N(R^{14})$ -C(O)-, -C(O)- $N(R^{14})$ -,  $-N(R^{14})$ -C(O)- $N(R^{14})$ -,  $-N(R^{14})$ - $R^{13}$  and  $R^{14}$  are each independently selected from hydrogen or methyl; and

R10 are each independently selected from the group consisting of:

- (1) C<sub>1-4</sub>alkyl,
- (2) C2-4alkenyl,
- (3) C<sub>2-4</sub>akynyl,
- 5 (4) C<sub>3-6</sub>cycloalkyl,
  - (5) C<sub>1-4</sub>alkoxy,
  - (6) aryl,
  - (7) aryl C<sub>1</sub>-4alkyl,
  - (8) HET,
- 10 (9) -C<sub>1-4</sub>alkyl-HET,
  - (10) aryloxy,
  - (11) aroyloxy,
  - (12) aryl C<sub>2-4</sub>alkenyl,
  - (13) aryl C<sub>2-6</sub>alkynyl,

15

wherein items (1) to (5) above and the alkyl portions of items (7) and (9) above and the alkenyl portion of item (12) above and the alkynyl portion of item (13) above are optionally substituted with from to three substituents independently selected from the group consisting of: halo, OR13, N(R14)2, C3-6cycloalkyl and C1-6alkyl-S(O)k-,

20 wherein k is 0, 1 or 2, and

wherein items (6), (8), (10) and (11) above and aryl portion of items (7), (12) and (13) above and the HET portion of item (9) above are optionally substituted with from one to three substituents independently selected from the group consisting of:

25

30

- (a) halo,
- (b)  $OR^{13}$ ,
- (c)  $N(R^{14})_2$ ,
- (d)  $C_{1-4}$ alkyl,
- (e) C<sub>2-4</sub>alkenyl,
- (f) C<sub>2-4</sub>akynyl,
- (g) aryl,
- (h) HET,
- (i) aryl C<sub>1</sub>-6alkyl,
- (j) aroyl,

- (k) aryloxy,
- (l) aryl C<sub>1-6</sub>alkoxy and
- (m) CN,

wherein items (d) to (f) above and the alkyl portions of item (i) above are optionally substituted with from one to three substituents independently selected from the group consisting of: halo, OR<sup>13</sup> and N(R<sup>14</sup>)<sub>2</sub>, and

wherein items (g), (h), (j) and (k) above and the aryl portions of items (i) and (l) above are optionally substituted with from one to three substituents independently selected from the group consisting of: halo, OR<sup>13</sup> and C<sub>1-4</sub>alkyl.

16. The compound according to Claim 15 wherein X is a bond, -C(O),  $-N(R^{14})$ -,  $-N(R^{14})$ -C(O)-, -C(O)- $N(R^{14})$ -,  $-N(R^{14})$ -C(O)-NH-; R<sup>13</sup> and R<sup>14</sup> are each independently from hydrogen or methyl; and R<sup>10</sup> are each independently selected from the group consisting of:

- (1) C3-6cycloalkyl,
- (2) aryl,
- (3) aryl C<sub>1-4</sub>alkyl,
- (4) HET,
- (5) -C<sub>1-4</sub>alkyl-HET,

10

15

20

25

(6) aryl C<sub>2-4</sub>alkenyl,

wherein item (1) above and the alkyl portions of items (3) and (5) above and the alkenyl portion of item (8) above are optionally substituted with from one to three substituents independently selected from the group consisting of: halo,  $OR^{13}$ ,  $N(R^{14})_2$ , and

wherein the aryl portion of items (2), (3), (6) and the HET portion of item (4) and (5) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of:

30 (a) halo,

(b)  $OR^{13}$ .

- (c)  $N(R^{14})_2$ ,
- (d) C<sub>1-4</sub>alkyl,
- (e) C<sub>2-4</sub>alkenyl,

35 (f) C<sub>2-4</sub>akynyl,

- (g) aryl,
- (h) HET,
- (i) aryl C<sub>1-6</sub>alkyl,
- (j) aroyl,

5

10

15

20

30

- (k) aryloxy,
- (l) aryl C<sub>1-6</sub>alkoxy and
- (m) CN,

wherein items (d) to (f) above and the alkyl portions of item (i) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo,  $OR^{13}$  and  $N(R^{14})_2$ , and

wherein items (g), (h), (j) and (k) above and the aryl portions of items (i) and (l) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR<sup>13</sup> and C<sub>1-4</sub>alkyl.

17. The compound according to Claim 16 wherein

 $R^{10}$  are each independently selected from the group consisting of:

- (1) C<sub>3-6</sub>cycloalkyl,
  - (2) aryl,
  - (3) aryl C<sub>1</sub>-4alkyl,
  - (4) HET,
  - (5) -C<sub>1-4</sub>alkyl-HET,
- 25 (6) aryl C<sub>2-4</sub>alkenyl,

wherein item (1) above and the alkyl portions of items (3) and (5) above and the alkenyl portion of item (8) above are optionally substituted with from one to three substituents independently selected from the group consisting of: halo, OR<sup>13</sup>, N(R<sup>14</sup>)<sub>2</sub>, and

wherein the HET portion of item (4) and (5) are optionally substituted with from one to three substituents selected from the group consisting of C<sub>1</sub>-4alkyl and aryl, and

wherein the aryl portion of items (2), (3), (6) above are optionally substituted with from one to three substituents independently selected from the group consisting of:

(a) halo, OR13. (b)  $N(R^{14})_{2}$ (c) (d) C<sub>1</sub>-4alkyl, 5 (e) C2-4alkenyl, C2-4akynyl, (f) (g) aryl, HET. (h) (i) aryl C<sub>1</sub>-6alkyl, 10 (j) aroyl, (k) aryloxy, (I) aryl C1:6alkoxy and

(m)

CN,

wherein items (d) to (f) above and the alkyl portions of item (i) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR<sup>13</sup> and N(R<sup>14</sup>)2, and

wherein items (g), (h), (j) and (k) above and the aryl portions of items (i) and (l) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR<sup>13</sup> and C<sub>1-4</sub>alkyl.

- 18. The compound according to Claim 3 wherein Y2 is CF3.
- 19. The compound according to Claim 18 wherein  $R^{10}$  is selected from the group consisting of:
  - (1) phenyl,
  - (2) benzyl, and
- 30 (3) HET, wherein HET is a 5-membered aromatic or non-aromatic monocyclic ring containing 1-3 heteroatoms selected from O, S and N,

wherein groups (1) to (3) above are optionally substituted with 1 to 3 substituents independently selected from the group consisting of:

35

20

25

- (a) halo,
- (b) C<sub>1-4</sub>alkyl, optionally substituted with hydroxy or 1 to 3

halo groups,

- (c) C<sub>1-4</sub>alkoxy, optionally substituted with 1 to 3 halo
- 5 groups,
- (d) NH2,
- (e) hydroxy, and
- (e) phėnyl or benzyl.
- 20. The compound according to Claim 3 wherein Y2 is hydrogen,
   X is a bond and R<sup>10</sup> is HET, wherein HET is a 5-membered aromatic or non-aromatic monocyclic ring containing 1-3 heteroatoms selected from O, S and N.
- 21. The compound according to Claim 20 wherein HET is selected from oxazolyl and imidazolyl.
  - 22. A compound selected from the group consisting of:

3	CF <sub>3</sub> H  HN  HN  HN  F
4	CF <sub>3</sub>
5	CF <sub>3</sub>
6	CF <sub>3</sub> HN P
7	CF <sub>3</sub>

PCT/US2003/029494

8	CF <sub>3</sub>
9	CF <sub>3</sub>
10	CF <sub>3</sub> HN  HN  F
11	CF <sub>3</sub> HN CI
12	CF <sub>3</sub> HN  Br

13	CF <sub>3</sub>
14	CF <sub>3</sub> N  HN  O  F  F
15	CF <sub>3</sub> HN O F
16	CF <sub>3</sub>
17	CF <sub>3</sub> N  HN  CI

r	
18	CF <sub>3</sub> HN FF
19	CF <sub>3</sub>
20	CF <sub>3</sub> HN N N N N N N N N N N N N N N N N N N
21	CF <sub>3</sub> HN NH <sub>2</sub>
22	CF <sub>3</sub> HN O HN F

<del>,</del>	
23	CF <sub>3</sub> HN  F
24	CF <sub>3</sub> HN HN F F
25	CF <sub>3</sub>
26	CF <sub>3</sub> HN  F
27	CF <sub>3</sub> HN CI

28	CF <sub>3</sub>
29	CF <sub>3</sub>
30	CF <sub>3</sub> HN OH
31	CF <sub>3</sub>
32	CF <sub>3</sub> NN HN O HN O F

33	CF <sub>3</sub>
	H I
	N, HN CCI
	CI
·	F
34	CF <sub>3</sub>
	NN HN F
	F CF <sub>3</sub>
35	H WO
	NN HN
	ОН
36	CF <sub>3</sub>
	HN
	F
37	CF <sub>3</sub>
	F F F
	F
L	Ė

	38	CF <sub>3</sub> HN  F  F  F  F  F  F  F  F  F  F  F  F  F
Helinian standard Lange over	39	CF <sub>3</sub> HI O OH  CF <sub>3</sub> CF <sub>3</sub>
(1) の	40	CF <sub>3</sub>
	41	CF <sub>3</sub>
	42	CF <sub>3</sub>

43	CF <sub>3</sub>
	F
44	CF <sub>3</sub> H N N N N N N N N N N N N N N N N N N
	F
45	CF <sub>3</sub>
	F
46	CF <sub>3</sub>
	F
47	CF <sub>3</sub>
	F

48	CF <sub>3</sub>
	F
49	CF <sub>3</sub>
	F
	CF <sub>3</sub> H Z Z Z K F N N N N N N N N N N N N N N N N N N
51 ·	CF <sub>3</sub>
52	CF <sub>3</sub>

53	CF <sub>3</sub> NN  NH <sub>2</sub>
54	CF <sub>3</sub> H N
55	CF <sub>3</sub> H N
56	CF <sub>3</sub> H N N N N N N N N N N N N N N N N N N

57	CF <sub>3</sub>
<b>.</b>	H H N
	N T T T T T T T T T T T T T T T T T T T
	)N~~~
58	CF <sub>3</sub>
	H H N F
	N. V.
	F
59	CF <sub>3</sub>
	H H
	N'N O F
	F
<u> </u>	É
60	CF <sub>3</sub> H N OH
	N N N OH
	N N
	F
61	CF <sub>3</sub>
	NN NH2
	N, N
L	É

62	CF <sub>3</sub>
	. F
63	CF <sub>3</sub>
64	CF <sub>3</sub>
65	CF <sub>3</sub>
66	CF <sub>3</sub> NH CF <sub>3</sub> CF <sub>3</sub>

67	CF <sub>3</sub>
68	CF <sub>3</sub>
69	CF <sub>3</sub>
70	F CF <sub>3</sub>
71	CF <sub>3</sub>

72	CF <sub>3</sub>
73	CF <sub>3</sub>
74	CF <sub>3</sub>
75	CF <sub>3</sub> NH O=S=O F
76	CF <sub>3</sub>

_ <del></del>	OF .
77	▼ ☐ H CF <sub>3</sub>
	NNH SEC
	0=\$=U
į	
	F <sup>É</sup> CF₃
78	· •   U U
ا	N NH
	N O N H
:	"
	F
79	CF <sub>3</sub>
	H WALL
	N NH NH
	ON F
	F
80	CF <sub>3</sub>
	NH F
	l "
	OF N
	F́ ΛCF <sub>3</sub>
81	, (H)
	N N N N N N N N N N N N N N N N N N N
	O N
L	<u> </u>

82	CO <sub>2</sub> Me CO <sub>2</sub> Me
	F CC Ma
83	CO <sub>2</sub> Me
,	N H CO <sub>2</sub> Me
84	FCO <sub>2</sub> Me
	NN CO <sub>2</sub> Me
85	CO <sub>2</sub> Me
	NN H CO <sub>2</sub> Me
<u> </u>	F

86	CO <sub>2</sub> Me
87	CF <sub>3</sub> CO <sub>2</sub> Me
88	CF <sub>3</sub> CO <sub>2</sub> Me
89	CF <sub>3</sub> H CO <sub>2</sub> Me

90	CF <sub>3</sub> CO <sub>2</sub> Me
91	F CO <sub>2</sub> Me
92	NN H CO₂Me
93	CO <sub>2</sub> Me NNCF <sub>3</sub> HCO <sub>2</sub> Me

94	,,,\CO <sub>2</sub> Me
34	II
	N HCO₂Me
	N H CO₂Me
	, N
	F ·
95	0 .
	N H
	N O O
	F
96	
70	
1	N H O
	F
97	
	N CO <sub>2</sub> Me
	N <sub>N</sub> H Se <sub>2</sub> me
	É

98	. ( )
	""CO-Ma
	N H CO₂Me
	N
	/ F .
99	
	$\sim \sim 1$
	N Ph
	N N N PH
	F
100	
	NN Ph
	N'N H N P
]	
101	F
101	HN
	N M M
	N N N N N N N N N N N N N N N N N N N
[	<u> </u>
L	F

102	N H N N
	N N N
	F
103	CO <sub>2</sub> Me
	N H CO₂Me
104	CF <sub>3</sub> CO₂Me
	NN H CO <sub>2</sub> Me
	F
105	CF <sub>3</sub>
·	N H CO <sub>2</sub> Me
	F

106	CF <sub>3</sub>
	H J. MCO
	N <sub>N</sub> HN
•	
107	CF <sub>3</sub>
	N H I
	HN TO
	°CF₃
108	CF <sub>3</sub>
	HN CF <sub>3</sub>
	CF <sub>3</sub>
	<del> </del>
109	CF <sub>3</sub>
	N HIN HIN
	N HN
<b>1</b> :	
	F
110	CF <sub>3</sub>
	N H P Q
_	F
	ĹÉ

111	CF <sub>3</sub>
	F CF <sub>3</sub>
112	H HN
113	CF <sub>3</sub>
	NN HN H
114	CF <sub>3</sub>
	F
115	CF <sub>3</sub>
	F

	<u> </u>
116	NN CF3
	F.
117	NN CF3
	F CF <sub>3</sub>
118	NNH NH
	E OF
119	CF <sub>3</sub>
,	
120	CF <sub>3</sub>
	F

121	N NH NH
	/ F
	CF <sub>3</sub>
123	CF <sub>3</sub>
124	CF <sub>3</sub>
125	CF <sub>3</sub>

105	CF <sub>3</sub>
126	<b>,</b> ∥⊎ ]
	N NH
·	N O O
	É CF <sub>3</sub>
127	1 ] <del>1</del> ] <del>1</del> ]
	N NH
	N O O
128	CF <sub>3</sub>
120	
	NH
	F
129	CF <sub>3</sub>
	NH H
]	N <sub>N</sub> F
	É CE
130	EF3
	N NH
	N V
	$\sim$
L	LÉ

131	CF <sub>3</sub>
132	CF <sub>3</sub>
133	CF <sub>3</sub>
134	CF <sub>3</sub>
135	CF <sub>3</sub>

23. A pharmaceutical composition comprising a compound according to Claim 1 in combination with a pharmaceutically acceptable carrier.

24. A method for treating a glucocorticoid receptor mediated disease or condition in a mammalian patient in need of such treatment comprising administering the patient a compound according to Claim 1 in an amount that is effective for treating the glucocorticoid receptor mediated disease or condition.

5

10

15

20

25

30

35

- 25. The method according to Claim 24 wherein the glucocorticoid receptor mediated disease or condition is selected from the group consisting of: tissue rejection, leukemias, lymphomas, Cushing's syndrome, acute adrenal insufficiency, congenital adrenal hyperplasia, rheumatic fever, polyarteritis nodosa, granulomatous polyarteritis, inhibition of myeloid cell lines, immune proliferation/apoptosis, HPA axis suppression and regulation, hypercortisolemia, stroke and spinal cord injury, hypercalcemia, hypergylcemia, acute adrenal insufficiency, chronic primary adrenal insufficiency, secondary adrenal insufficiency, congenital adrenal hyperplasia, cerebral edema, thrombocytopenia, Little's syndrome, obesity, metabolic syndrome, inflammatory bowel disease, systemic lupus erythematosus, polyartitis nodosa, Wegener's granulomatosis, giant cell arteritis, rheumatoid arthritis, juvenile rheumatoid arthritis, uveitis, hay fever, allergic rhinitis, urticaria, angioneurotic edema, chronic obstructive pulmonary disease, asthma, tendonitis, bursitis, Crohn's disease, ulcerative colitis, autoimmune chronic active hepatitis, organ transplantation, hepatitis, cirrhosis, inflammatory scalp alopecia, panniculitis, psoriasis, discoid lupus erythematosus, inflamed cysts, atopic dermatitis, pyoderma gangrenosum, pemphigus vulgaris, buflous pernphigoid, systemic lupus erythematosus, dermatomyositis, herpes gestationis, eosinophilic fasciitis, relapsing polychondritis, inflammatory vasculitis, sarcoidosis, Sweet's disease, type I reactive leprosy, capillary hemangiomas, contact dermatitis, atopic dermatitis, lichen planus, exfoliative dermatitus, erythema nodosum, acne, hirsutism, toxic epidermal necrolysis, erythema multiform, cutaneous T-cell lymphoma, Human Immunodeficiency Virus (HIV), cell apoptosis, cancer, Kaposi's sarcoma, retinitis pigmentosa, cognitive performance, memory and learning enhancement, depression, addiction, mood disorders, chronic fatigue syndrome. schizophrenia, sleep disorders, and anxiety.
- 26. The method according to Claim 24 wherein the glucocorticoid receptor mediated disease or condition is selected from the group consisting of: tissue rejection, Cushing's syndrome, inflammatory bowel disease, systemic lupus

erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, hay fever, allergic rhinitis, asthma, organ transplantation, inflammatory scalp alopecia, psoriasis, discoid lupus erythematosus, and depression.

- 5 27. A method of selectively modulating the activation, repression, agonism and antagonism effects of the glucocorticoid receptor in a mammal comprising administering to the mammal a compound according to Claim 1 in an amount that is effective to modulate the glucocorticoid receptor.
- 28. A method of partially or fully antagonizing, repressing agonizing or modulating the glucocorticoid receptor in a mammal comprising administering to the mammal an effective amount of compound according to Claim 1.

## 29. A compound according to Claim 1 of Formula Id

15

or a pharmaceutically acceptable salt thereof, wherein

20

- $R^{10}$  is a 5-membered aromatic or non-aromatic mono-cyclic ring containing 1-3 heteroatoms selected from O, S, and N, and
- R<sup>10</sup> is mono-substituted with phenyl, wherein phenyl is optionally substituted with 1-3 substituents independently selected from halo, C<sub>1-4</sub>alkyl and C<sub>1-4</sub>alkoxy.
  - 30. The compound according to Claim 29 wherein  $R^{10}$  is oxazolyl, oxadiazolyl or thiazolyl.

31. The compound according to Claim 30 wherein  $R^{10}$  is oxazolyl.